Fecal Transplantation in Hematopoietic Transplantation
Authors: Jonathan U. Peled, Marcel R.M. van den Brink
Journal: Journal of Clinical Oncology (2023)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML. May 26, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01169 Journal of Clinical Oncology - published online before print October 23, 2023 PMID: 37871256 Fecal Transplantation in Hematopoietic Transplantation Jonathan U. Peled , MD, PhD1,2xJonathan U. PeledSearch for articles by this author and Marcel R.M. van den Brink , MD, PhD1,2,3xMarcel R.M. van den BrinkSearch for articles by this author Show More 1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY2Weill Cornell College of Medicine, New York, NY3Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.23.01169 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by NHLBI NIH Award K08HL143189, MSKCC Cancer Center Core Grant P30 CA008748, the Society of Memorial Sloan Kettering Cancer Center (J.U.P.). M.R.M.V.D.B. is supported by National Cancer Institute award numbers, R01-CA228358, R01-CA228308, P30 CA008748 MSK Cancer Center Support Grant/Core Grant and P01-CA023766; National Heart, Lung, and Blood Institute (NHLBI) award number R01-HL123340 and R01-HL147584; National Institute on Aging award number P01-AG052359, and Tri Institutional Stem Cell Initiative. Additional funding was received from The Lymphoma Foundation, The Susan and Peter Solomon Family Fund, The Solomon Microbiome Nutrition and Cancer Program, Cycle for Survival, Parker Institute for Cancer Immunotherapy, Paula and Rodger Riney Multiple Myeloma Research Initiative, Starr Cancer Consortium, and Seres Therapeutics.AUTHOR CONTRIBUTIONSConception and design: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFecal Transplantation in Hematopoietic TransplantationThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jonathan U. PeledStock and Other Ownership Interests: Postbiotics Inc, Seres Therapeutics (Inst)Consulting or Advisory Role: Da Volterra, MaaT Pharma, CSL BehringResearch Funding: Seres TherapeuticsPatents, Royalties, Other Intellectual Property: IP licensing fees, Seres Therapeutics, filed intellectual property applications related to the microbiomeTravel, Accommodations, Expenses: Seres TherapeuticsOpen Payments Link: https://openpaymentsdata.cms.gov/physician/566299Marcel R.M. van den BrinkHonoraria: Seres Therapeutics, Merck, Magenta Therapeutics, WindMIL, WindMIL, Rheos Medicines, Frazier Healthcare Partners, Nektar, Notch Therapeutics, Forty Seven, Priothera, Ceramedix, Lygenesis, Pluto Immunotherapeutics, GlaxoSmithKline, Da Volterra, Novartis, Synthekine, BeiGeneConsulting or Advisory Role: Seres TherapeuticsResearch Funding: Seres TherapeuticsPatents, Royalties, Other Intellectual Property: Dr van den Brink receives royalties from Wolters Kluwer, and he has intellectual property Licensing with Seres Therapeutics and Juno TherapeuticsTravel, Accommodations, Expenses: Rheos MedicinesOther Relationship: DKMSUncompensated Relationships: Seres therapeutics, Notch Therapeutics, Pluto ImmunotherapeuticsNo other potential conflicts of interest were reported. Companion Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML